Spirogen
London
About Spirogen
Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. Spirogen's principal technology involves modification of members of a group of naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs). The company was founded in 2000, has 18 employees and is private equity funded.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $16.4M
- Funding stage: M&A
- Last round: Private Equity (Oct 2009)
- Website: spirogen.com
- Phone: 44 (0) 20 7278 0555
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/spirogen-2717559 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.